Takeda Pharmaceutical (TYO: 4502) has pulled the plug on a gene therapy collaboration with fellow Japanese drugmaker JCR Pharmaceuticals (TYO: 4552).
Since March 2022, the companies have been working together on gene therapies, using adeno-associated viruses (AAV) combined with the JCR J-Brain Cargo technology.
In March 2023, JCR received a pre-clinical proof-of-concept milestone payment for confirming that the technology is able to accomplish therapeutically relevant effects, using a mouse model.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze